Healthcare · Revenue & Growth
Productized Lead Qualification for Pharmaceuticals
We design, build, and run AI-native lead qualification for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native lead qualification for pharmaceuticals is a phased engagement (Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)) that ships a production workflow on top of CRM and medical information systems, moves speed to lead by +45 pts against the pharmaceuticals baseline, and is operated under revenue & growth governance from day one.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Lead Qualification
- Intent cluster
- Revenue & Growth
- Primary KPI
- speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction
- Top benchmark
- CRM data quality (account completeness): 42% → 87% (+45 pts)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)
- Team size
- 1 senior delivery + 1 part-time integration eng
- Discovery price
- $5k · 2-week sprint
- Build price
- $15k–$22k · 6-8 weeks
Primary outcome
separate serious buyers from noise faster
What we ship
AI qualification assistant, scoring rubric, routing rules, and CRM governance
KPIs we report on
speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction
Why Pharmaceuticals teams hire us for this
medical response time, content approval cycle time, field productivity, and safety case throughput. That is the line that gets quoted in the board deck for pharmaceuticals, and that is the line our work moves. Everything we ship on lead qualification — the workflow design, the prompt library, the reviewer queues, the evaluation harness — exists to push that metric. If a deliverable does not connect to it, we strip it out of the SoW.
Recent industry benchmarks (Gartner, Salesforce Research) show pharmaceuticals revenue teams spend 60-70% of their week on non-selling activities. AI-native delivery targets that non-selling block first.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of lead qualification in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
CRM data quality (account completeness) Forrester B2B Insights: human-only CRM hygiene typically degrades within 6 months | 42% | 87% | +45 pts |
Pipeline conversion (SQL → opportunity) Lift attributed to better intent scoring + faster handoff from AI to AE | 18% | 27% | +50% |
Cost per qualified meeting Includes AI infra cost, SDR time, and overhead allocation | $420 | $95 | −77% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
The unit of operation on lead qualification is not a model call — it is a case (a ticket, a claim, a record, a request) that flows from intake to outcome. We instrument every case end-to-end: where it came in, what context it was matched against, what action was taken, who reviewed it, how long it took, whether the outcome held. For pharmaceuticals teams, that case-level telemetry is what makes the workflow operationally legible.
What we build inside the workflow
A strong implementation starts with a clear inventory of the current work. For Pharmaceuticals, that means understanding how data moves through CRM, medical information systems, safety databases, content approval tools, data lakes, who owns each decision, and where handoffs slow the team down. We document current cycle time, error rates, quality review steps, rework, and the volume of requests or records flowing through the process. The automation layer will scores inbound demand, summarizes context, checks fit, asks missing questions, and routes leads to the right owner.
Reference architecture
4-layer AI-native workflow for revenue & growth
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Revenue & Growth →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for lead qualification in pharmaceuticals.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | +50% |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Revenue engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$5k
2-week sprint
Phase 2 · Build
$15k–$22k
6-8 weeks
Phase 3 · Run
$2k–$3k / mo
optional, hourly bank also available
~$25k–$45k typical year 1 (60% take the run option for ~6 months)
Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for lead qualification
Reference inputs below are typical for pharmaceuticals teams in the revenue cluster. Adjust them to match your situation.
Projected
Current monthly cost
$24,000
AI-native monthly cost
$7,920
Annual savings
$192,960
67% cost reduction · ~468 operator-hours freed / month
Governance and risk controls
medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails. Those concerns are addressed by architecture, not by policy documents. We ship a control map alongside the workflow — what data sources are approved, what model versions are deployed, what reviewer queues exist, what escalation paths trigger, what attestation cadence we run. The map is on the same dashboard as the workflow metrics, not in a shared drive nobody reads.
How we report ROI
For pharmaceuticals CFOs evaluating lead qualification engagements, the cleanest ROI framing is unit economics: cost per case before vs after, throughput per FTE before vs after, error rate before vs after. We instrument all three from the Discovery baseline and report against them weekly. No abstract "productivity gain" claims; concrete dollars and minutes.
Common pitfall & mitigation
The failure mode we see most often on AI-native lead qualification engagements in pharmaceuticals contexts.
Volume without quality
Teams scale outbound 5× but reply rate collapses because the AI sends generic pitches
Per-prospect context retrieval (intent data + recent triggers) before any draft. Reviewer queue on first 500 sends to calibrate.
Build internally or work with us
Pharmaceuticals teams that build successfully in-house tend to have an existing ML platform, a labelled data culture, and a product manager dedicated to the workflow. If any of those is missing, the project tends to stall at proof-of-concept. We replace those three dependencies with a scoped engagement and a senior delivery team.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from pharmaceuticals, not only generic test prompts.
- Ask how we will move speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native lead qualification in pharmaceuticals is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate lead qualification in pharmaceuticals with AI?+
We map the existing lead qualification workflow inside pharmaceuticals, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your CRM, medical information systems, safety databases, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction, and improve it weekly.
What does it cost to automate lead qualification for a pharmaceuticals company?+
Three phases, billed separately. Discovery sprint: $5k (2-week sprint). Build engagement: $15k–$22k (6-8 weeks). Run retainer: $2k–$3k / mo (optional, hourly bank also available). ~$25k–$45k typical year 1 (60% take the run option for ~6 months). Outbound, growth, or revenue-ops workflow, integration with your CRM, weekly operating review during Run.
What is the best AI agent for lead qualification in pharmaceuticals?+
There is no single "best" off-the-shelf agent for lead qualification in pharmaceuticals — the right architecture depends on your CRM setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for CRM and medical information systems integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI lead qualification for pharmaceuticals?+
A thin-slice deployment in 2-week sprint after Discovery, with real pharmaceuticals data and real reviewers. The full Build phase runs 6-8 weeks. By day 90, speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent pharmaceuticals workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you measure revenue impact for lead qualification in pharmaceuticals?+
We instrument speed to lead, MQL to SQL conversion, sales acceptance rate, and wasted meeting reduction from day one, paired with sector-level metrics such as medical response time, content approval cycle time, field productivity, and safety case throughput. We report against baseline weekly during Run, and we publish a 90-day impact recap.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- OECD AI Principles — OECD
- EU AI Act — European Commission
- B2B Buying Disconnect: Buying Decisions are Made Without Sellers — Forrester
- Generative AI Impact on Marketing & Sales — McKinsey
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Start the engagement
Book a discovery call for Pharmaceuticals
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.